Microbiology and management of Staphylococcus aureus lacrimal system infections: A 10-year retrospective study
by Niloufar Bineshfar, Kevin D. Clauss, Wendy W. Lee, Darlene Miller
PurposeTo assess the in vitro efficacy of common antimicrobial agents used empirically for methicillin- resistant and sensitive Staphylococcus aureus (MRSA and MSSA) infections of the lacrimal system.
MethodsA retrospective review of culture-proven S. aureus isolates retrieved from lacrimal system samples collected between January 2013–December 2022 was performed. Microbiologic characteristics such as in vitro susceptibility as well as clinical characteristics including history of recent ocular surgery, presence of lacrimal biomaterial implant, anti-microbial regimen, and treatments outcome were collected.
ResultsOne hundred and sixteen S. aureus isolates (patients = 116) were identified. Thirty-one (27.4%) and 22 (19.5%) patients had recent ocular procedure and lacrimal intubation, respectively. Fifty (44.2%) patients received a combination of oral and topical antibiotics as first line of treatment. The most common empirically utilized antibiotics were β-lactams (38.9%) and polymyxin B/ trimethoprim (31.0%). The antibiotic regimen was changed at least once in 20.5% of patients due to ineffectiveness. Of the patients with positive cultures from the lacrimal excretory apparatus, 37.3% underwent surgery as part of the treatment approach. Of all isolates identified 44.8% were MRSA. Among the fluoroquinolones, the resistance rate was 38.8% for ciprofloxacin and 30.4% for moxifloxacin, with significantly higher resistance rates in MRSA (P-value <0.0001). The resistance rates for trimethoprim/sulfamethoxazole (TMP/SXT) and gentamicin were 8.6% and 3.4%, retrospectively.
ConclusionsThere is low in vitro efficacy of commonly used antimicrobials such as β-lactams and fluoroquinolones in our study population; thus, we recommend opting for trimethoprim/sulfamethoxazole and gentamicin for systemic and topical single-agent treatments.